<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823468</url>
  </required_header>
  <id_info>
    <org_study_id>FYYY-FLK-202001</org_study_id>
    <nct_id>NCT04823468</nct_id>
  </id_info>
  <brief_title>Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma</brief_title>
  <official_title>Effect of Oral Nutritional Supplements From the Beginning of Radiotherapy on Body Weight Loss of Patients With Nasopharyngeal Carcinoma and Its Cost-effectiveness Analysis: A Prospective Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinsheng Hong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Nanping First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quanzhou First Hospital Affiliated to Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhangzhou Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>900th hospital of the joint logistics team, PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan Hospital Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Fujian Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concurrent chemoradiotherapy(CCRT) is the principal treatment for nasopharyngeal&#xD;
      carcinoma(NPC). Studies have shown that malnutrition is very common in patients with NPC&#xD;
      after chemoradiotherapy. Malnutrition can lead to weight loss, treatment interruption,&#xD;
      prolonged stay in hospital, increased treatment costs, reduced tolerance to anti-tumor&#xD;
      therapy, reduced quality of life and shortened survival time. Nutritional intervention can&#xD;
      improve the nutritional status, reduce treatment-related toxicity and improve the survival of&#xD;
      patients with NPC.&#xD;
&#xD;
      The first choice of nutritional intervention is oral nutritional supplements(ONS). Some&#xD;
      retrospective studies with small samples have found that early nutritional intervention can&#xD;
      reduce weight loss and severe oral mucositis in patients with NPC, compared with late&#xD;
      nutritional intervention. Therefore, the investigators proposed the hypothesis that ONS from&#xD;
      the beginning of radiotherapy can reduce the nutritional impairment, treatment-related&#xD;
      toxicity and treatment costs of patients with NPC, and improve their quality of life. The aim&#xD;
      of this multicenter randomized controlled clinical trial is to evaluate the efficacy and cost&#xD;
      utility of ONS from the beginning to the end of radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of weight loss &gt; 5%</measure>
    <time_frame>From time of randomization to the date of radiotherapy ends, up to 7 weeks</time_frame>
    <description>The percentage of patients whose body weight decreased more than 5% over baseline, body weight (in kilograms) are measured at baseline and weekly during the course of radiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PG-SGA Score</measure>
    <time_frame>From time of randomization to the date of radiotherapy ends, up to 7 weeks</time_frame>
    <description>The scores assessed by Patient-Generated Subjective Nutrition Assessment (PG-SGA) at baseline and weekly during the course of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of participants with grade ≥3 oral mucositis</measure>
    <time_frame>During the course of radiotherapy, up to 7 weeks</time_frame>
    <description>Incidence of grade 3-4 oral mucositis assessed by CTCAE v5.0, evaluated weekly during radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of radiotherapy interruption</measure>
    <time_frame>During the course of radiotherapy, up to 7 weeks</time_frame>
    <description>The number of days that radiotherapy was interrupted due to treatment-related toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 v3.0 (EORTC QLQ-C30 v3.0)</measure>
    <time_frame>From time of randomization to the date of radiotherapy ends, up to 7 weeks</time_frame>
    <description>The standard scores assessed by the EORTC QLQ-C30 v3.0 at baseline and the end of radiotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increment Cost-Utility Ratio (ICUR）</measure>
    <time_frame>During the course of chemoradiotherapy, up to 7 weeks</time_frame>
    <description>The Increment cost-utility ratio is used to assess the economics of ONS, which is calculated as incremental cost divided by incremental utility.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Nutritional Support</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to conventional dietary instruction and individualized nutritional counselling, patients were given additional ONS (Abbott®Ensure of 55.8 g tid) from the beginning to the end of radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conventional dietary instruction and individualized nutritional counselling from the beginning to the end of radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Abbott®Ensure</intervention_name>
    <description>Abbott®Ensure: 55.8 g each time, three times a day, from the beginning to the end of radiotherapy</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity Modulated Radiation Therapy</intervention_name>
    <description>The prescribed dose was 68-76 Gy to Planning target volume of the primary tumor (PTVnx), 66-70 Gy to Planning target volume of the cervical lymph node (PTVnd), 60-64 Gy to planning target volume 1 (PTV1), and 50-54 Gy to planning target volume 2 (PTV2) in 30-33 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>80-100 mg/m² cisplatin given intravenously every 3 weeks concurrently with radiotherapy.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly histologic diagnosis of nasopharyngeal carcinoma;&#xD;
&#xD;
          -  All genders, range from 18-70 years old;&#xD;
&#xD;
          -  Clinical stage II-IVa according to the 8th edition of the Union for International&#xD;
             Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system;&#xD;
&#xD;
          -  Patient-Generated Subjective Nutrition Assessment (PG-SGA) score ≤8;&#xD;
&#xD;
          -  Main organ functions test should be satisfied the following conditions: (1) Absolute&#xD;
             neutrophil count (ANC) ≥1.5×10^9/L; (2) Platelet (PLT) ≥80×10^9/L; (3) Hemoglobin (Hb)&#xD;
             ≥90 g/L; (4) Bilirubin &lt; 1.5 times the upper limit of normal value (ULN), aspartate&#xD;
             aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 times the upper limit&#xD;
             of normal value; (5) Creatinine &lt; 1.5 times the upper limit of normal value or&#xD;
             creatinine clearance rate &gt;60 ml/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients whose energy intake is less than 60% of the target energy requirement for 3&#xD;
             days or more;&#xD;
&#xD;
          -  Have or are suffering from other malignant tumors;&#xD;
&#xD;
          -  Refuse concurrent chemoradiotherapy;&#xD;
&#xD;
          -  With diabetics, galactosemia, or sever metabolic diseases or endocrine diseases;&#xD;
&#xD;
          -  Cannot take oral or enteral nutrition, including intestinal obstruction, severe short&#xD;
             bowel syndrome or high output fistula, or with severe digestive system diseases;&#xD;
&#xD;
          -  Known allergic reaction to any component of Abbott®Ensure, or severe allergic&#xD;
             constitution;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  With previous or ongoing clinical trials;&#xD;
&#xD;
          -  Refuse to sign inform consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinsheng Hong</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Fujian Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinsheng Hong</last_name>
    <phone>+8613799375732</phone>
    <email>13799375732@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benhua Xu</last_name>
      <phone>13696884375</phone>
      <email>benhuaxu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinsheng Hong</last_name>
      <phone>+86 13799375732</phone>
      <email>13799375732@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Su</last_name>
      <phone>+86 13950396918</phone>
      <email>lily2230@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shaojun Lin</last_name>
      <phone>13860603879</phone>
      <email>linshaojun@yeah.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>900th hospital of the joint logistics team, PLA</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhichao Fu</last_name>
      <phone>13774562945</phone>
      <email>fauster1112@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Nanping First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Nanping</city>
        <state>Fujian</state>
        <zip>353000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rongqiang Liu</last_name>
      <phone>18960610588</phone>
      <email>jiniris@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quanzhou First Hospital Affiliated to Fujian Medical University</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <zip>362000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zilong Chen</last_name>
      <phone>13505039984</phone>
      <email>czll1234@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <zip>362000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhigang Bai</last_name>
      <phone>13805969375</phone>
      <email>drbpc65@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qin Lin</last_name>
      <phone>13806000926</phone>
      <email>linqin05@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haijie Lu</last_name>
      <phone>13696982871</phone>
      <email>luhaijiedr@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhangzhou Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Zhangzhou</city>
        <state>Fujian</state>
        <zip>363000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianli Huang</last_name>
      <phone>13606959887</phone>
      <email>zzhuangjl@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Guan</last_name>
      <phone>13632102247</phone>
      <email>51643930@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaqian Han</last_name>
      <phone>18673176667</phone>
      <email>hanyaqiancs@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaochang Gong</last_name>
      <phone>13970020755</phone>
      <email>gxcanddw@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>July 25, 2021</last_update_submitted>
  <last_update_submitted_qc>July 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Jinsheng Hong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>Nutritional Support</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Dietary Supplements</keyword>
  <keyword>Body Weight</keyword>
  <keyword>Cost-Effectiveness Analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

